EGFR and non-small cell lung carcinoma: NEJ009 was a phase II study published in 2020 and aimed to assess both the safety and efficacy of administering gefitinib alone or in combination with chemotherapy (carboplatin plus pemetrexed) to 345 EGFR mutation-positive NSCLC patients [50].